Clinical Trial Update: Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of a novel adjuvanted hepatitis B vaccine in healthy volunteers with HLA-DQ2; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HBV vaccine (adjuvanted) (Hepatitis B vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED